세계 카테터 관련 혈류감염(CRBSI) 시장 규모는 2024년부터 2031년까지 예측 기간 동안 연평균 5.35%의 CAGR을 기록하며 2023년 17억 1,000만 달러에서 2031년에는 25억 9,000만 달러 규모로 성장할 것으로 예상됩니다.
시장 성장의 원동력은 침습적 의료 시술의 증가, 고령화 인구의 증가, 세계 각지의 만성질환 유병률 증가 등입니다.
CRBSI의 예방 및 치료를 위해 향상된 진단 방법 및 항균 코팅 카테터와 같은 첨단 제품 및 기술의 채택이 증가하고 있으며, CRBSI의 장기적인 도전은 최첨단 솔루션 개발을 촉진하고 있습니다. 부적절한 멸균 절차 및 병원 내 감염의 증가는 시장 수요를 증가시키는 주요 요인 중 일부입니다. 연구 기관과 주요 사업자들이 환자 안전을 촉진하는 첨단 제품 개발에 주력하고 있는 것도 시장 확대를 더욱 촉진하고 있습니다.
CRBSI에 대한 연구 활동 증가
이 질환과 관련된 다양한 합병증을 이해하고 CRBSI를 추적하여 궁극적으로 발병률을 낮추기 위해 다양한 연구 활동과 조사가 진행되고 있으며, 2023년에는 유지 혈액 투석 환자의 CRBSI와 관련된 요인을 밝히기 위해 가나의 3차 병원에서 실시된 횡단적 연구가 발표되었습니다. 혈액투석을 받는 환자에서 CRBSI의 높은 유병률을 발견한 횡단적 연구가 발표되었습니다.
신규 치료법 개발을 위한 신규 사업자의 노력 증가
CRBSI 치료 및 예방 솔루션을 개발하기 위해 다양한 주요 업체들이 노력하고 있으며, 2023년 CorMedix, Inc.는 DefenCath에 대한 FDA 승인을 받았습니다. 헤파린과 타우로리딘을 함유한 이 카테터 잠금 솔루션은 중앙정맥 카테터를 통해 만성 혈액투석을 받는 성인의 CRBSI를 치료하고 예방하는 데 도움이 될 수 있습니다. 수성, 무균, 투명, 무방부제인 DefenCath는 미국에서 승인된 최초이자 유일한 항균 카테터 잠금 솔루션입니다.
북미가 큰 시장 점유율을 차지한다
이 지역의 시장 확대는 노인 인구 증가, 카테터 삽입의 필요성 증가, 기존 의료 인프라의 존재, 혈액 관련 감염 치료를 위한 급속한 기술 발전으로 인한 것으로, Population Reference Bureau에 따르면, 65세 이상 미국인은 2022년에서 2050년까지 47% 증가할 것으로 추정됩니다. 그 수는 5800만 명(2022년)에서 8200만 명(2050년)으로 증가할 것으로 예상되며, 65세 이상 연령층이 차지하는 비율은 17%에서 23%로 증가할 것으로 예상됩니다.
세계 카테터 관련 혈류감염(CRBSI) 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 분류 및 지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global catheter-related bloodstream infection market is projected to witness a CAGR of 5.35% during the forecast period 2024-2031, growing from USD 1.71 billion in 2023 to USD 2.59 billion in 2031F. The market growth is driven by a rise in the number of invasive medical procedures, an increasing aging population, and a growing prevalence of chronic diseases in various regions across the globe.
The rising adoption of advanced products and technologies for the prevention and treatment of catheter-related bloodstream infections, including enhanced diagnostic methods and antimicrobial-coated catheters, is providing lucrative growth opportunities for the market. The long-posed challenges of catheter-related bloodstream infections are prompting the development of cutting-edge solutions. The increasing incidence related to improper aseptic procedures and the growing prevalence of hospital-acquired infections are some of the major factors bolstering the market demand. The increasing emphasis of research organizations and major market players on the development of advanced products that promote patient safety is further supporting the market expansion.
According to a ScienceDirect article, in the Elsevier Journal in December 2023, a team of researchers and The Flume Catheter Company, in the United Kingdom is working on the development and testing of a FLUME urinary catheter with relocated drainage holes and protected tip. The retaining balloon supports a static load of 700 grams and reduced trauma when forced evulsion was modeled. The catheter design aims to enhance patient safety and comfort while maximizing bladder drainage.
Increasing Research Activities on CRBSI
Various research activities and studies are being conducted to understand the different complications associated with the disease and track CRBSI to ultimately reduce the number of cases. In 2023, a cross-sectional study conducted at a tertiary hospital in Ghana to determine the factors associated with catheter-related bloodstream infections among patients who were on maintenance hemodialysis was published. The cross-sectional hospital-based study was conducted on patients who were receiving maintenance hemodialysis via central venous catheters. The risk factors that were predictive of catheter-related bloodstream infections were determined with the help of multivariate analysis using logistic regression. High prevalence of catheter-related bloodstream infections was noted among patients undergoing hemodialysis. The most common causative agent was Coagulase negative Staphylococci. As per the conclusion of the study, there is a high requirement for infection surveillance units in the renal unit for tracking catheter-related bloodstream infections and taking significant measures to reduce these infections. It was noted that the prevalence of catheter-related bloodstream infections among the participants was 34.2%. A contributing factor for the prevalence of CRBSI in the participants of the study may be the lack of utilization of antiseptic or antibiotic lock system.
Increasing Efforts Towards Development of Novel Treatments by Market Players
Various major market players are dedicated towards developing treatment and prevention solutions for catheter-related bloodstream infections. In 2023, CorMedix, Inc. received FDA approval for DefenCath. The heparin and taurolidine containing catheter lock solution aids in treating and preventing catheter-related bloodstream infections in adults undergoing chronic hemodialysis through a central venous catheter. The aqueous-based, sterile, clear, and preservative-free DefenCath is the first and only antimicrobial catheter lock solution approved in the United States. DefenCath will allow healthcare providers to reduce the risk of infections in patients suffering from underlying kidney failure. The approval of the product was based upon the findings from the Phase 3 LOCK-IT-100 clinical study. The multicentral, randomized, active control, double-blind trial analyzed the safety and efficacy of DefenCath in lowering the incidences of catheter-related bloodstream infections in patients undergoing chronic hemodialysis due to kidney failure.
North America Accounts for a Significant Market Share
The expansion of the market in the region can be attributed to the growth of the geriatric population, increased requirement for catheters insertion, presence of a well-established healthcare infrastructure and rapid technological advancements for treatment of blood related infections. According to the Population Reference Bureau, the number of Americans aging 65 years and older is estimated to witness a 47% increase from 2022 to 2050. The number is projected to increase from 58 million (in 2022) to 82 million (by 2050). The share of the 65-and-older age group is expected to increase from 17% to 23%.
Frequent catheterization is often required in the elderly if they are suffering from urinary retention, continence, cancer, and pressure ulcers, increasing the risk of catheter-related bloodstream infections. Long-term catheterization is preferred by various caretakers and healthcare professionals as it reduces their burden and allows them to focus on the other requirements of the patient. However, catheterization for long intervals of time can often lead to complications and cause catheter-related bloodstream infections.
Increasing Research Activities on Coagulase-Negative Staphylococcus Support Segment Growth
Undergoing research activities are expected to determine how to effectively manage catheter-related bloodstream infection caused by coagulase-negative staphylococcus. As per the clinical guidelines, the management of coagulase-negative staphylococcus causing catheter-related bloodstream infections requires antibiotic treatment for five to seven days along with catheter removal. According to an Antibiotics article published in May 2023, in National Library of Medicine, randomized clinical trials are being conducted with the aim to determine whether no administration of antibiotic therapy is effective and safe in low-risk episodes of catheter-related bloodstream infections caused by coagulase-negative staphylococcus. In the study, the patients suffering from CRBSI caused by coagulase-negative staphylococcus were randomized 1:1 after the withdrawal of catheter were opted to receive or not receive parenteral antibiotics that act against the isolated strain. The secondary endpoints of the study were septic embolism, persistent bacteremia, time until the disappearance of the fever, and time until microbiological cure. The primary endpoint was the occurrence of any complications related to the antibiotic therapy or bacteremia within the ninety days of the follow-up.
Online Pharmacies Expected to Witness Significant Growth Over the Forecast Period
Owing to the convenience offered by online pharmacies, including fast deliveries, this distribution channel has evolved from an alternative method for procuring medication and has gained immense popularity. Over the past few years more patients have recognized the convenient nature of shopping across these pharmacies, supplanting the reliance on retail pharmacies. According to a survey funded by Sanofi Consumer Healthcare, respondents indicated various advantages of online pharmacies including reduced costs for patients, convenience, and increased access for patients.
Online pharmacies eliminate the requirement of calling in a prescription, walking or driving to the pharmacy and waiting in line. The unparalleled levels of confidentiality and privacy offered by online pharmacies is further boosting the popularity of the distribution channel. The growth of the segment is facilitated by the rapid expansion of the internet services and ease of mail-order trade. Furthermore, the price transparency and accessibility offered by online pharmacies is encouraging consumers to adopt these channels for purchasing different medication.
Future Market Scenario (2024 - 2031F)
The catheter-related bloodstream infection (CRBSI) market is expected to witness significant growth in the coming years due to several factors including increasing emphasis on research and development activities and growing requirement for catheters in elderly patients.
The rising investments towards the healthcare and pharmaceutical industries is expected to offer lucrative growth opportunities to the market.
Various studies are being conducted to examine the risk of catheter-related bloodstream infections in patients with hemodialysis catheters. For instance, Zealand University Hospital is conducting an interventional study to examine the effects of ethanol (70%) as a lock solution. The study is estimated to conclude in April 2025.
University of Zurich is on the phase 4 of their interventional study aiming to understand the effect of vancomycin after catheter replacement. The randomized controlled trial will study the effect of a single dose of vancomycin on infection resolution after the replacement of catheter for suspected central line-associated bloodstream infection. The study is expected to conclude in December 2024.
Key Players Landscape and Outlook
Key participants in the catheter-related bloodstream infection market include Pfizer Inc., Citius Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., CorMedix, Inc., and Teva Pharmaceuticals. Increasing research and development activities and strategic partnerships between leading market players is expected to offer lucrative growth opportunities to the market.
In 2023, CorMedix, Inc. received FDA approval for DefenCath. According to FDA, the drug will reduce incidences of catheter-related bloodstream infections in adults receiving chronic hemodialysis via a central catheter due to kidney failure.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work